Brilliant Violet 421™ anti-mouse CD45.2

Antibodies Single
Sony
104
Flow Cytometry
Mouse IgG2a, κ
Mouse
B10.S mouse thymocytes and splenocytes
1149155
$191.00

Description

CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the microg size, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. For flow cytometric staining using the microL sizes , the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block)
2. Yakura H, et al. 1986. J. Immunol. 136:2729. (Block)
3. Suzuki K, et al. 2000. Immunity 13:691. (IHC)
4. Shen FW, et al. 1986. Immunogenetics 24:146. (IP)
5. Baldwin TA and Hogquist KA. 2007. J. Immunol. 179:837.
6. Pascal V, et al. 2007. J. Immunol. 179:1751.
7. Burman AC, et al. 2007. Blood 110:1064.
8. Kincaid EZ, et al. 2007. J. Immunol. 179:3187.
9. Phan TG, et al. 2007. Nature Immunol. 8:992.
10. Nakano-Yokomizo T, et al. 2011. J. Exp Med. 208:1661. PubMed
11. Wen T, et al. 2013. PNAS. 110:6067. PubMed
12. Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed